Clinical Trials Logo

Filter by:
NCT ID: NCT05632328 Not yet recruiting - Pancreatic Cancer Clinical Trials

AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Balstilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy. The names of the study drugs involved in this study are: - AGEN1423 - Balstilimab Participants will receive study treatment for about 2 years and will be followed for 1 year after.

NCT ID: NCT05637567 Not yet recruiting - Clinical trials for Pancreatic Cancer Resectable

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

ASAP
Start date: April 2024
Phase: Phase 2
Study type: Interventional

This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head. The main question it aims to answer is: Do patients treated perioperatively with aspirin develop less metastasis after curative resection of pancreatic head tumors? Participants will be asked to : - take a daily aspirin tablet starting 1-4 weeks before surgery until 6 months after surgery - participate in regular follow-up visits.

NCT ID: NCT05646641 Not yet recruiting - Fibromyalgia Clinical Trials

Strength Training in Fibromyalgia on Balance, Neuromuscular Performance and Symptoms

Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is verify the effects of a 8 weeks strength training, on balance, neuromuscular performance and symptomatology of fibromyalgia.

NCT ID: NCT05686629 Not yet recruiting - Clinical trials for Novel COVID-19-Infected Pneumonia

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.

NCT ID: NCT05688839 Not yet recruiting - Clinical trials for Novel COVID-19-Infected Pneumonia

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

COVID-19
Start date: April 2024
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo parallel control study and is expected to enroll 20-60 eligible patients with severe novel coronavirus pneumonia.

NCT ID: NCT05705141 Not yet recruiting - Chronic Hepatitis b Clinical Trials

The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B

Start date: April 2024
Phase:
Study type: Observational

Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, the rising incidence of metabolic syndrome (MetS) is another grim health burden. Combined MetS affects the metabolic function of hepatocytes, which are responsible for providing HBV replication. Antiviral therapy is an effective measure to reduce the risk of cirrhosis and liver cancer in patients with chronic CHB. Combined MetS may affect the antiviral efficacy in patients with CHB.This prospective observational study examines the differences in HBeAg serological conversion rates between HBeAg-positive CHB patients with and without MS who received first-line oral antivirals for 144 weeks.

NCT ID: NCT05708755 Not yet recruiting - Clinical trials for Lung Transplant; Complications

CMV Immunity Monitoring in Lung Transplant Recipients

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

NCT ID: NCT05728255 Not yet recruiting - Syncope Clinical Trials

Assessment of the Mechanism of Non-cardiac Syncope

2STEPS
Start date: April 2024
Phase:
Study type: Observational

Identifying the mechanism of non-cardiac syncope is the essential prerequisite for an effective personalized therapy. Aim of this multicentre, prospective, cross-sectional, observational study is to assess effectiveness and diagnostic yield of a two-step standardized assessment which consists of 24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM), limited to patients ≥40-year-old, standing test, and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table

NCT ID: NCT05729958 Not yet recruiting - Clinical trials for Ankle Osteoarthritis

Total Ankle Replacement Using Guides, Expert Versus Trainee

TARGET
Start date: April 2024
Phase:
Study type: Observational

Patient Specific Instrumentation (PSI) is thought to quicken joint arthroplasty surgery by shortening the operation time and improving alignment. Studies about the learning curve of PSI for total ankle replacement (TAR) are lacking because it was only introduced in 2014. The investigators believe that PSI could give a beginning ankle surgeon, or surgeons new to TAR, an advantage since PSI facilitates the complex TAR procedure. As such, the availability of TAR in Dutch patients with end-stage ankle osteoarthritis could be extended. To estimate this potential of PSI for TAR, the investigators aim (1) to compare the alignment accuracy of TAR performed using PSI between a beginning and an experienced orthopedic surgeon, and (2) to determine the learning curve of TAR performed using PSI for a beginning foot and ankle specialist by comparing the operative time, complications, and patient-reported outcomes with those of an experienced specialist.

NCT ID: NCT05731375 Not yet recruiting - B-cell Lymphoma Clinical Trials

Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage

MUSCLE
Start date: April 2024
Phase:
Study type: Observational

The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and cardiac muscles in muscles in large B- or T-cell lymphoma patients during treatment with (R-)CHOP. The main question it aims to answer is: • Can 31P-MRS be used to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles in large B- or T-cell lymphoma patients during treatment with (R-)CHOP? To be able to answer this main question, participants will undergo 31P-MRS imaging of the calf muscles and of the heart 3 times during the study period.